These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 32728220)

  • 1. Targeting CD39 in cancer.
    Moesta AK; Li XY; Smyth MJ
    Nat Rev Immunol; 2020 Dec; 20(12):739-755. PubMed ID: 32728220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD39 - A bright target for cancer immunotherapy.
    Guo S; Han F; Zhu W
    Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory role of CD39 and CD73 in tumor immunity.
    Kaplinsky N; Williams K; Watkins D; Adams M; Stanbery L; Nemunaitis J
    Future Oncol; 2024; 20(19):1367-1380. PubMed ID: 38652041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the adenosine pathway for cancer immunotherapy.
    Hammami A; Allard D; Allard B; Stagg J
    Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
    Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
    Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
    [No Abstract]   [Full Text] [Related]  

  • 7. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
    Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
    Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
    J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome.
    Bertelli R; Bodria M; Nobile M; Alloisio S; Barbieri R; Montobbio G; Patrone P; Ghiggeri GM
    Clin Exp Immunol; 2011 Oct; 166(1):55-63. PubMed ID: 21762125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the mechanism of anti-CD39 immune checkpoint therapy.
    Allard D; Allard B; Stagg J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD39 and CD73 in immunity and inflammation.
    Antonioli L; Pacher P; Vizi ES; Haskó G
    Trends Mol Med; 2013 Jun; 19(6):355-67. PubMed ID: 23601906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
    Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
    Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the expression and function of the P2X7 receptor and ART1 in human regulatory T-cell subsets.
    Cortés-Garcia JD; López-López C; Cortez-Espinosa N; García-Hernández MH; Guzmán-Flores JM; Layseca-Espinosa E; Portales-Cervantes L; Portales-Pérez DP
    Immunobiology; 2016 Jan; 221(1):84-93. PubMed ID: 26307000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting adenosine for cancer immunotherapy.
    Leone RD; Emens LA
    J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of ecto-nucleoside triphosphate diphosphohydrolase 1 (CD39) involved in regulating extracellular ATP-mediated innate immune responses in Japanese flounder (Paralichthys olivaceus).
    Li S; Chen X; Wang N; Li J; Feng Y; Sun J
    Mol Immunol; 2019 Aug; 112():10-21. PubMed ID: 31075558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purinergic signaling during intestinal inflammation.
    Longhi MS; Moss A; Jiang ZG; Robson SC
    J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes.
    Raczkowski F; Rissiek A; Ricklefs I; Heiss K; Schumacher V; Wundenberg K; Haag F; Koch-Nolte F; Tolosa E; Mittrücker HW
    PLoS One; 2018; 13(5):e0197151. PubMed ID: 29742141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ENTPD1/CD39 is a promising therapeutic target in oncology.
    Bastid J; Cottalorda-Regairaz A; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A
    Oncogene; 2013 Apr; 32(14):1743-51. PubMed ID: 22751118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.